| DESCRIPTION | - AL-LAZIKANI et al., J. Mol. Biol., (19970000), vol. 273, pages 927 - 948 |
| DESCRIPTION | - ALWING et al., Eur. Respir. J., (19930000), vol. 6, pages 1368 - 1370 |
| DESCRIPTION | - BJERKE et al., Respir. Med.,, (19960000), vol. 90, no. 5, pages 271 - 277 |
| DESCRIPTION | - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138 |
| DESCRIPTION | - HOPKINS et al., Clin. Otolaryngol., (20090000), vol. 34, pages 447 - 454 |
| DESCRIPTION | - JIA et al., J Allergy Clin Immunol, (20120000), vol. 130, pages 647 - 654 |
| DESCRIPTION | - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533 |
| DESCRIPTION | - LILLY et al., J. Allergy Clin. Immunol., (19990000), vol. 104, pages 786 - 790 |
| DESCRIPTION | - MARECHAL et al., Anticancer Res, (19880000), vol. 8, pages 677 - 680 |
| DESCRIPTION | - MARTIN et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 9268 - 9272 |
| DESCRIPTION | - MOCHIZUKI et al., J. Immunol., (19980000), vol. 160, no. 1, pages 60 - 68 |
| DESCRIPTION | - MORDENTI et al., Pharmaceut. Res., (19910000), vol. 8, page 1351 |
| DESCRIPTION | - POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027 |
| DESCRIPTION | - Remington's Pharmaceutical Sciences, Mack Publishing Company |
| DESCRIPTION | - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201 |
| DESCRIPTION | - TANG et al., Eur. Respir. J., (20100000), vol. 35, pages 757 - 760 |
| DESCRIPTION | - TAYLOR et al., Nucl. Acids Res., (19920000), vol. 20, pages 6287 - 6295 |
| DESCRIPTION | - VAN DE POL et al., Allergy, (20120000), vol. 67, no. 1, pages 67 - 73 |
| DESCRIPTION | - WU et al., J. Biol. Chem., (19870000), vol. 262, pages 4429 - 4432 |
| OPPOSITION | - Al-Ramli Wisam, Mohamed Al Samri, Qutayba Hamid, "TH-17 Cell-Related Cytokines' Potential Role in the Pathogenesis of Severe Asthma", Journal of Asthma, (20080101), vol. 45, no. S1, pages 41 - 44, XP055945001 |
| OPPOSITION | - Anonymous, "GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION", GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION, (20090101), GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION, (20220720), XP055944397 |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01312961 Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma", clinicaltrials.gov, (20120820), clinicaltrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT01312961?A=31&B=31&C=merged#StudyPageTop , (20220720), XP055944378 |
| OPPOSITION | - Anonymous, "International Nonpropietary Names for Pharmaceutical Substance (INN)", WHO Drug Information, (20120101), vol. 26, no. 4, pages 401 - 471, XP055945232 |
| OPPOSITION | - Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) / Dénominations communes internationales des Substances pharmaceutiques (DCI) - List 108", WHO Drug Information, (20120101), vol. 26, no. 4, pages 401 - 471, XP055945085 |
| OPPOSITION | - Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN), List 108", WHO Drug Information, (20120101), vol. 26, no. 4, pages 401 - 471, XP055932074 |
| OPPOSITION | - Anonymous, "REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL AND OPERATING RESULTS", R, egeneron, (20120213), R, (20220720), XP055944380 |
| OPPOSITION | - Anonymous, "Regeneron Science to MedicineTM", J.P. Morgan Healthcare Conference, San Francisco, San Francisco, (20130101), J.P. Morgan Healthcare Conference, (20220722), XP055945238 |
| OPPOSITION | - Anonymous, "Targeting IL-5 in severe asthma: a DREAM come true?", the lancet, (20120818), vol. 380, pages 626 - 127, XP055944382 |
| OPPOSITION | - BIRKETT D. J., "Pharmacokinetics made easy 11 Designing dose regimens", Aust Prescr, vol. 19, no. 3, (19960701), pages 76 - 78, URL: https://www.nps.org.au/australian-prescriber/articles/pharmacokinetics-made-easy-11-designing-dose-regimens, XP055136785 |
| OPPOSITION | - FIRSZT et al., "Pharmacotherapy of Severe Asthma", Curr Opin Pharmacol, (20100600), vol. 10, no. 3, pages 266 - 271, XP027137700 |
| OPPOSITION | - Gibaldi, Milo, Biopharmaceutics and Clinical Pharmacokinetics, 4th ed., (19910101), pages 12 - 13, XP055945117 |
| OPPOSITION | - "Global Strategy for Asthma Management and Prevention", GINA Report 2011, (20111200), URL: www.qinasthma.org, XP055944374 |
| OPPOSITION | - "Global Strategy for Asthma Management and Prevention", GINA Report 2012, (20121200), URL: www.qinasthma.org, XP055944377 |
| OPPOSITION | - LOMMATZSCH MAREK ET AL, "Severe asthma: definition, diagnosis and treatment.", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, (20141212), vol. 111, no. 50, ISSN 1866-0452, pages 847 - 855, XP002789189 |
| OPPOSITION | - M.E. Aulton, "Chapter 19: Dosage regimes", Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone , (20011001), pages 275 - 278, XP055404622 |
| OPPOSITION | - Mould Diane R; Sweeney Kevin R D, "The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB , (20070101), vol. 10, no. 1, ISSN 1367-6733, pages 84 - 96, XP009097022 |
| OPPOSITION | - Pollart Susan M., Kurtis S. Edward, "Overview of Changes to Asthma Guidelines: Diagnosis and Screening ", American Family Physician, (20090501), vol. 79, no. 9, pages 761 - 767, XP055944965 |
| OPPOSITION | - SPECTOR et al., "Is a single blood eosinophil count a reliable marker for ''eosinophilic asthma?", Journal of Asthma, (20120820), vol. 49, no. 8, pages 1 - 4, XP055944391 |
| OPPOSITION | - SZEFLER et al., "Asthma Outcomes: Biomarkers", J Allergy Clin Immunol, (20120301), vol. 129, pages S 9 - 23, XP055944385 |
| OPPOSITION | - Cara J. Bossley; Louise Fleming; Atul Gupta; Nicolas Regamey; Jennifer Frith; Timothy Oates; Lemonia Tsartsali; Clare M. Lloyd; Andrew Bush; Sejal Saglani;, "Pediatric severe asthma is characterized by eosinophilia and remodeling without T2 cytokines", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120123), vol. 129, no. 4, doi:10.1016/j.jaci.2012.01.059, ISSN 0091-6749, pages 974 - 982.e13, XP028478864 |
| OPPOSITION | - De Boever Erika H., Ashman Claire, Cahn Anthony P., Locantore Nicholas W., Overend Phil, Pouliquen Isabelle J., Serone Adrian P., Wright Tracey J., Jenkins Mair M., Panesar Inderpal S., Thiagarajah Sivayogan S., Wenzel Sally E., "Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20140401), vol. 133, no. 4, doi:10.1016/j.jaci.2014.01.002, ISSN 0091-6749, pages 989 - 996.e4, XP055945227 |
| OPPOSITION | - DARVEAX et al., "Biologics in asthma - the next step to personalised treatment", J Allergy Clin Immunol Pract, (20150300), vol. 3, no. 2, doi:10.1016/j.jaip.2014.09.014, pages 152 - 161, XP055535036 |
| OPPOSITION | - PAVORD et al., "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial", Lancet, (20120818), vol. 380, doi:10.1016/S0140-6736(12)60988-X, pages 651 - 59, XP002714506 |
| OPPOSITION | - EISENSTEIN, "Something new under the skin", Nature Biotechnology, (20110207), vol. 29, no. 2, doi:10.1038/nbt.1768, pages 107 - 109, XP009152843 |
| OPPOSITION | - WENZEL, "Asthma phenotypes: the evolution from clinical to molecular approaches (review)", Nature Medicine, (20120504), vol. 18, no. 5, pages 716 - 725, XP055944372 |
| OPPOSITION | - WESCHLER, "Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma", N Engl J Med, (20130521), vol. 368, doi:10.1056/NEJMe1305426, pages 2511 - 2513, XP009180486 |
| OPPOSITION | - Wenzel et al., "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, (20130521), vol. 368, doi:10.1056/NEJMoa1304048, pages 2455 - 66, XP008165248 |
| OPPOSITION | - WENZEL et al., "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, (20130521), vol. 368, no. 26, doi:10.1056/NEJMoa1304048, pages 2455 - 66, XP008165248 |
| OPPOSITION | - Wenzel et al., "Dupilumab in Persistent Asthma with Elevated Eosinophil Levels", The New England Journal of Medicine, US , (20130627), vol. 368, no. 26, doi:10.1056/NEJMoa1304048, ISSN 0028-4793, pages 2455 - 2466, XP008165248 |
| OPPOSITION | - Wenzel Sally; Ford Linda; Pearlman David; Spector Sheldon; Sher Lawrence; Skobieranda Franck; Wang Lin; Kirkesseli Stephane; Rocklin Ross; Bock Brian; Hamilton Jennifer; Ming Jeffrey E; Radin Allen; Stahl Neil; Yancopoulos George D; Graham Neil; Pirozzi Gianluca, "Dupilumab in Persistent Asthma with Elevated Eosinophil Levels", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130627), vol. 368, no. 26, doi:10.1056/NEJMoa1304048, ISSN 0028-4793, pages 2455 - 2466, XP008165248 |
| OPPOSITION | - WENZEL, "Severe Asthma: from characteristics to phenotypes to endotypes (review)", Clinical & Experimental Allergy, (20120118), vol. 42, pages 650 - 658, XP055944371 |
| OPPOSITION | - O'Byrne et al., "Severe asthma: future treatments", Clinical & Experimental Allergy, UK , (20120501), vol. 42, no. 5, doi:10.1111/j.1365-2222.2012.03965.x, ISSN 0954-7894, pages 706 - 711, XP055945097 |
| OPPOSITION | - OTULANA et al., "A Phase 2b Study of Inhaled Pitrakinra, an IL -4 / IL -13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma", American Journal of Respiratory and Critical Care Medicine, (20110518), vol. 183, doi:10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A6179, page A6179, XP002716819 |
| OPPOSITION | - Wenzel Sally, "Severe Asthma in Adults", American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, US, US , (20050715), vol. 172, no. 2, doi:10.1164/rccm.200409-1181PP, ISSN 1073-449X, pages 149 - 160, XP055944998 |
| OPPOSITION | - P. G. Woodruff, B. Modrek, D. F. Choy, G. Jia, A. R. Abbas, A. Ellwanger, J. R. Arron, L. L. Koth, J. V. Fahy, "T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma", American Journal of Respiratory and Critical Care Medicine, (20090901), vol. 180, no. 5, doi:10.1164/rccm.200903-0392OC, ISSN 1073449X, pages 388 - 395, XP055049862 |
| OPPOSITION | - CORREN et al., "A randomized, controlled, Phase 2 study of AMG 317, an IL -4Ra antagonist, in patients with asthma", Am J Respir Crit Care Med, (20100107), vol. 181, no. 8, doi:10.1164/rccm.200909-1448OC, pages 788 - 96, XP055013586 |
| OPPOSITION | - Corren et al., "A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R Antagonist, in Patients with Asthma", American Journal of Respiratory and Critical Care Medicine, (20100415), vol. 181, no. 8, doi:10.1164/rccm.200909-1448OC, ISSN 1073449X, pages 788 - 796, XP055013586 |
| OPPOSITION | - J. Corren, W. Busse, E. O. Meltzer, L. Mansfield, G. Bensch, J. Fahrenholz, S. E. Wenzel, Y. Chon, M. Dunn, H. H. Weng, S. L. Lin, "A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R Antagonist, in Patients with Asthma", American Journal of Respiratory and Critical Care Medicine, (20100415), vol. 181, no. 8, doi:10.1164/rccm.200909-1448OC, ISSN 1073449X, pages 788 - 796, XP055013586 |
| OPPOSITION | - Borish Larry, "IL-4 and IL-13 Dual Antagonism : A Promising Approach to the Dilemma of Generating Effective Asthma Biotherapeutics", American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, US, US , (20100415), vol. 181, no. 8, doi:10.1164/rccm.201002-0147ED, ISSN 1073-449X, pages 769 - 770, XP055944399 |
| OPPOSITION | - Panaccione Remo, Ghosh Subrata, "Review: Optimal use of biologics in the management of Crohn’s disease", Therapeutic Advances in Gastroenterology, (20100501), vol. 3, no. 3, doi:10.1177/1756283X09357579, ISSN 1756-2848, pages 179 - 189, XP055928707 |
| OPPOSITION | - Joanne Shannon, Ernst Pierre, Yamauchi Yasuhiro, Olivenstein Ronald, Lemiere Catherine, Foley Susan, Cicora Leo, Ludwig Mara, Hamid Qutayba, Martin James G., "Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma", CHEST, American College of Chest Physicians, US, US , (20080201), vol. 133, no. 2, doi:10.1378/chest.07-1881, ISSN 0012-3692, pages 420 - 426, XP055535048 |
| OPPOSITION | - Brusselle Guy, Bracke Ken, "Targeting Immune Pathways for Therapy in Asthma and Chronic Obstructive Pulmonary Disease", Annals of the American Thoracic Society, (20141201), vol. 11, no. Supplement 5, doi:10.1513/AnnalsATS.201403-118AW, ISSN 2329-6933, pages S322 - S328, XP055932126 |
| OPPOSITION | - Gibson Pg, "Corticosteroids - clinical applications: exacerbations of asthma in adults", AUSTRALIAN PRESCRIBER, AUSTRALIAN GOVERNMENT - PUBLISHING SERVICE, CANBERRA, AU, AU , (19960401), vol. 16, no. 2, doi:10.18773/austprescr.1996.049, ISSN 0312-8008, pages 44 - 47, XP055944949 |
| OPPOSITION | - Liang Zhenyu, Zhao Haijin, Lv Yanhua, Li Rui, Dong Hangming, Liu Laiyu, Xia Yang, Hou Changchun, Cai Shaoxi, Zou Fei, "Moderate Accuracy of Peripheral Eosinophil Count for Predicting Eosinophilic Phenotype in Steroid-Naïve Non-Atopic Adult Asthmatics", INTERNAL MEDICINE., JAPANESE SOCIETY OF INTERNAL MEDICINE, TOKYO., JP, JP , (20120101), vol. 51, no. 7, doi:10.2169/internalmedicine.51.6834, ISSN 0918-2918, pages 717 - 722, XP055932140 |
| OPPOSITION | - Sandeep Thirunavukkarasu, Roopakala Mysoresubrahmanyam, Silvia Chickballapur Rayappawilma Delphine, Chandrashekara Srikantaiah, Rao Mohan, "Evaluation of serum immunoglobulin E levels in bronchial asthma", Lung India, (20100101), vol. 27, no. 3, doi:10.4103/0970-2113.68312, ISSN 0970-2113, pages 138 - 140, XP055945226 |
| SEARCH | - JARED DARVEAUX ET AL, "Biologics in Asthma-The Next Step Toward Personalized Treatment", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY : AN OFFICIAL JOURNAL OF AAAAI, AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY, (20150301), vol. 3, no. 2, doi:10.1016/j.jaip.2014.09.014, ISSN 2213-2198, pages 152 - 160, XP055535036 [T] 1-14 * page 8, paragraph 3 - paragraph 4 * |
| SEARCH | - METERAN HOWRAMAN ET AL, "Novel monoclonal treatments in severe asthma", JOURNAL OF ASTHMA : DEVOTED TO ASTHMA AND RELATED CONDITIONS, INFORMA HEALTHCARE, USA, vol. 54, no. 10, doi:10.1080/02770903.2017.1296157, ISSN 1532-4303, (20171130), pages 991 - 1011, (20170316), XP009510079 [T] 1-14 * page 1007, column l, paragraph 4 - column r, paragraph 5 * * table 4 * |
| SEARCH | - DIEGO BAGNASCO ET AL, "A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY., CH, (20160101), vol. 170, no. 2, doi:10.1159/000447692, ISSN 1018-2438, pages 122 - 131, XP055535051 [T] 1-14 * page 127, column l, paragraph 2 - column r, paragraph 3 * |
| SEARCH | - J. CORREN ET AL, "A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R Antagonist, in Patients with Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (20100415), vol. 181, no. 8, doi:10.1164/rccm.200909-1448OC, ISSN 1073-449X, pages 788 - 796, XP055013586 [A] 1-14 * abstract * * page 788, column r, paragraph l - page 789, column l, paragraph 3 * * page 792, column l, paragraph 2 * |
| SEARCH | - JOANNE SHANNON ET AL, "Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma", CHEST, US, (20080201), vol. 133, no. 2, doi:10.1378/chest.07-1881, ISSN 0012-3692, pages 420 - 426, XP055535048 [I] 1-14 * abstract * |
